RPE65 and Retinal dystrophy: The approval of voretigene neparvovec-rzyl (Luxturna®) for RPE65-associated retinal dystrophy marked a milestone in gene therapy, while ongoing clinical trials now explore gene editing (CRISPR), RNA-based correction strategies, optogenetics, and stem cell transplantation.